Loading…
DYAI
Dyadic International Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 26745T101
$0.61-3.91%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $24.6M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.21
- ROE
- —
- Profit margin
- -200.46%
- Revenue growth
- -0.60%
- Beta
- 1.02
- 52-week high
- $1.60
- 52-week low
- $0.60
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -90.6% over 5Y.
today you would have $74.82▼ -92.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 9 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.94 | $1.75 | $1.61 | $1.23 | $4.52 | $5.38 | $5.18 | $1.89 | $1.39 | |
| P/S | 39.0x | 11.1x | 15.1x | 16.1x | 12.1x | 53.1x | 92.5x | 84.3x | 39.0x | 51.9x |
| P/B | 5.2x | 27.8x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TVRDTvardi Therapeutics, Inc. | $1.82 | — | 1.2x | — | -126.19% | $24.28M |
| TXMDTherapeuticsMD, Inc. | $2.16 | — | 0.9x | — | -1.08% | $25M |
| AYTUAYTU Biopharma Inc | $2.25 | — | 0.7x | — | -97.42% | $24.15M |
| EVAXEvaxion A/S | $3.01 |
About the company
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
- 5
- Jupiter, United States
Company description provided by Yahoo Finance.